SEC Company Response from IMMUTEP Ltd (IMMP, PRRUF) (CIK 0001506184) (IMMP) — Oct 31, 2017
IMMUTEP Ltd (IMMP, PRRUF) (CIK 0001506184)
Date: Oct. 31, 2017 · CIK: 0001506184 · Accession: 0001193125-17-326670
AI Filing Summary & Sentiment
File numbers found in text: 333-221021
Letter
Prima BioMed Ltd
Level 12, 95 Pitt Street
Sydney, 2000 New South Wales
Australia
October 31, 2017
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
RE:
Prima BioMed Ltd
Registration Statement on Form F-3
Securities Act File No. 333-221021
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Prima BioMed Ltd (the “Registrant”) hereby respectfully requests acceleration of its Registration Statement on Form F-3, filed on October 19, 2017, so that it may become effective at 4:00 p.m. (Eastern time) on November 2, 2017, or as soon as practicable thereafter.
We request that we be notified of such effectiveness by a telephone call to Christopher H. Cunningham, K&L Gates LLP, at (206) 370-7639.
The Registrant hereby acknowledges that, if the Securities and Exchange Commission (or its staff, acting pursuant to delegated authority) (the “Commission”) declares the filing effective, such action:
(i)
does not foreclose the Commission from taking any action with respect to the filing;
(ii)
does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
(iii)
may not be asserted by the Registrant as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Prima BioMed Ltd
Show Raw Text
CORRESP 1 filename1.htm CORRESP Prima BioMed Ltd Level 12, 95 Pitt Street Sydney, 2000 New South Wales Australia October 31, 2017 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 RE: Prima BioMed Ltd Registration Statement on Form F-3 Securities Act File No. 333-221021 REQUEST FOR ACCELERATION OF EFFECTIVENESS Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Prima BioMed Ltd (the “Registrant”) hereby respectfully requests acceleration of its Registration Statement on Form F-3, filed on October 19, 2017, so that it may become effective at 4:00 p.m. (Eastern time) on November 2, 2017, or as soon as practicable thereafter. We request that we be notified of such effectiveness by a telephone call to Christopher H. Cunningham, K&L Gates LLP, at (206) 370-7639. The Registrant hereby acknowledges that, if the Securities and Exchange Commission (or its staff, acting pursuant to delegated authority) (the “Commission”) declares the filing effective, such action: (i) does not foreclose the Commission from taking any action with respect to the filing; (ii) does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) may not be asserted by the Registrant as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, Prima BioMed Ltd By: /s/ Deanne Miller Deanne Miller COO, General Counsel & Secretary